-+ 0.00%
-+ 0.00%
-+ 0.00%

DUPIXENT® (DUPILUMAB) APPROVED IN THE U.S. AS THE ONLY TARGETED MEDICINE TO TREAT PATIENTS WITH BULLOUS PEMPHIGOID (BP)

Reuters·06/20/2025 05:00:53

Please log in to view news